1. Home
  2. MLYS vs FPI Comparison

MLYS vs FPI Comparison

Compare MLYS & FPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • FPI
  • Stock Information
  • Founded
  • MLYS 2019
  • FPI 2013
  • Country
  • MLYS United States
  • FPI United States
  • Employees
  • MLYS N/A
  • FPI N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • FPI Real Estate Investment Trusts
  • Sector
  • MLYS Health Care
  • FPI Real Estate
  • Exchange
  • MLYS Nasdaq
  • FPI Nasdaq
  • Market Cap
  • MLYS 1.0B
  • FPI 516.0M
  • IPO Year
  • MLYS 2023
  • FPI 2014
  • Fundamental
  • Price
  • MLYS $14.63
  • FPI $11.18
  • Analyst Decision
  • MLYS Strong Buy
  • FPI
  • Analyst Count
  • MLYS 4
  • FPI 0
  • Target Price
  • MLYS $27.00
  • FPI N/A
  • AVG Volume (30 Days)
  • MLYS 885.1K
  • FPI 468.0K
  • Earning Date
  • MLYS 08-12-2025
  • FPI 07-23-2025
  • Dividend Yield
  • MLYS N/A
  • FPI 2.15%
  • EPS Growth
  • MLYS N/A
  • FPI 104.48
  • EPS
  • MLYS N/A
  • FPI 1.09
  • Revenue
  • MLYS N/A
  • FPI $56,535,000.00
  • Revenue This Year
  • MLYS N/A
  • FPI N/A
  • Revenue Next Year
  • MLYS N/A
  • FPI N/A
  • P/E Ratio
  • MLYS N/A
  • FPI $10.29
  • Revenue Growth
  • MLYS N/A
  • FPI N/A
  • 52 Week Low
  • MLYS $8.24
  • FPI $9.66
  • 52 Week High
  • MLYS $18.38
  • FPI $12.87
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 54.08
  • FPI 49.75
  • Support Level
  • MLYS $14.07
  • FPI $10.97
  • Resistance Level
  • MLYS $14.70
  • FPI $11.69
  • Average True Range (ATR)
  • MLYS 0.69
  • FPI 0.16
  • MACD
  • MLYS 0.15
  • FPI -0.05
  • Stochastic Oscillator
  • MLYS 80.69
  • FPI 43.36

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About FPI Farmland Partners Inc.

Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.

Share on Social Networks: